3M™ Skin and Nasal Antiseptic
(Povidone-Iodine Solution 5% w/w [0.5% available iodine] USP)
Patient Preoperative Skin Preparation
3M™ Skin and Nasal Antiseptic (Povidone-Iodine Solution 5% w/w [0.5% available iodine] USP) Patient Preoperative Skin Preparation was designed to help reduce the risk of factors that can lead to SSIs. With this product you can make a change that makes a real difference.
Approximately 30% of surgical patients are already colonized with S. aureus³
80% of SSIs from S. aureus come from the patient’s own nasal flora⁴⁻⁶
One SSI can cost a facility up to an additional $60K per incident⁷
Providers can take control of preoperative nasal decolonization with 3M™ Skin and Nasal Antiseptic. This simple, one-time application reduces nasal bacteria, including S. aureus, by 99.5% in just one hour and maintains this reduction for at least 12 hours.⁸ As part of a comprehensive preoperative protocol, 3M™ Skin and Nasal Antiseptic is an important tool to help reduce SSIs while supporting antibiotic stewardship.²’⁹⁻¹²
This white paper provides examples of the clinical evidence and findings on 3M™ Skin and Nasal Antiseptic that demonstrate its efficacy, cost effectiveness and overall performance.
3M™ Skin and Nasal Antiseptic is the only nasal antiseptic supported by 10 investigator initiated studies. Download a summary of clinical evidence to learn how 3M™ Skin and Nasal Antiseptic is different from other solutions. Inside these summaries you’ll clearly learn that not all nasal antiseptics are created equally.
3M™ Skin and Nasal Antiseptic works with a quick one-time application prior to surgery and easily fits into the preoperative protocol, so compliance is ensured.
1. 3M Study-05-011017.
2. Phillips M, Rosenberg A, Shopsin B, et al. Preventing surgical site infections: A randomized, open-label trial of nasal mup. ointment and nasal povidone-iodine solution. Infect Control Hosp Epidemiol. 2014;35:826-32
3. Kuehnert MJ, Kruszon-Moran D, Hill HA, et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001–2002. J Infect Dis. 2006;193:172-179.
4. Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mup. to prevent postoperative Staphylococcus aureus infections. N Engl J Med. 2002;346:1871-1877.
5. Kalmeijer MD, van Nieuwland-Bollen E, Bogaers-Hofman D, deBaere GAJ, Kluytmans JAJW. Nasal carriage of Staphylococcus aureus is a major risk factor for surgical-site infections in orthopedic surgery. Infect Control Hosp Epidemiol. 2000;21:319-323.
6. Kluytmans JAJW, Mouton JW, Ijzerman EPF, et al. Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis. 1995;171:216-219.
7. Anderson DJ, Kaye KS, Chen LF, et al. Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: a multi-center matched outcomes study. PLoS ONE. 2009;4:e8305.
8. 3M Study-05-011100.
9. Bebko SP, Green DM, Awad SS. Effect of a preoperative decontamination protocol on surgical site infections in patients undergoing elective orthopedic surgery with hardware implantation. JAMA Surg.15;150:390-295.
10. Brown L, Shelly M, Greene L, et al. The effect of universal intranasal povidone iodine antisepsis on total joint replacement surgical site infections. Presented at the APIC National Conference, Anaheim, CA, June 2014.
11. Waibel ML. Revisiting process improvement for total joint arthroplasty SSI. Presented at the APIC National Conference, Fort Lauderdale, FL, June 2013.
12. Hogenmiller JR, Hamilton J, Clayman T, et al. Preventing orthopedic total joint replacement SSIs through a comprehensive best practice bundle/checklist. Presented at the APIC National Conference, Baltimore, MD, June 2011.